Thermo Fisher Scientific Share Price Berne S.E.

Equities

TFS

US8835561023

Advanced Medical Equipment & Technology

Delayed Berne S.E. 09:30:02 02/04/2024 pm IST 5-day change 1st Jan Change
514.5 CHF -0.35% Intraday chart for Thermo Fisher Scientific -0.35% +19.58%

Financials

Sales 2024 * 4.3TCr 3.84TCr 3,59200Cr Sales 2025 * 4.61TCr 4.12TCr 3,84900Cr Capitalization 22TCr 19TCr 18,15400Cr
Net income 2024 * 614.6Cr 549.17Cr 51TCr Net income 2025 * 697.1Cr 622.89Cr 58TCr EV / Sales 2024 * 5.6 x
Net Debt 2024 * 2.35TCr 2.1TCr 1,96100Cr Net Debt 2025 * 1.91TCr 1.71TCr 1,59800Cr EV / Sales 2025 * 5.13 x
P/E ratio 2024 *
35.8 x
P/E ratio 2025 *
30.7 x
Employees -
Yield 2024 *
0.26%
Yield 2025 *
0.29%
Free-Float 86.04%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 01/01/01
Director of Finance/CFO 57 01/01/01
Chief Tech/Sci/R&D Officer - 01/19/01
Members of the board TitleAgeSince
Chief Executive Officer 56 01/01/01
Director/Board Member 67 30/12/30
Director/Board Member 62 01/22/01
More insiders
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
569.6 USD
Average target price
627.5 USD
Spread / Average Target
+10.16%
Consensus